BCAR3 and BCAR3-related competing endogenous RNA expression in hepatocellular carcinoma and their prognostic value

Table 1 Association between BCAR3 expression and the clinical parameters in patients with hepatocellular carcinoma in The Cancer Genome Altas, n (%)

Characteristics	Low expression of BCAR3	High expression of BCAR3	P value
n	187	187
Gender			0.912
Male	127 (34)	126 (33.7)
Female	60 (16)	61 (16.3)
Age			0.275
≤ 60	94 (25.2)	83 (22.3)
> 60	93 (24.9)	103 (27.6)
Tumor status			0.014
Tumor free	111 (31.3)	91 (25.6)
With tumor	64 (18)	89 (25.1)
Pathologic T stage			0.085
T1 and T2	146 (39.4)	132 (35.6)
T3	37 (10)	43 (11.6)
T4	3 (0.8)	10 (2.7)
Pathologic M stage			0.667
M0	138 (50.7)	130 (47.8)
M1	3 (1.1)	1 (0.4)
AFP (ng/mL)			0.056
≤ 400	110 (39.3)	105 (37.5)
> 400	42 (15)	23 (8.2)
Histological type			0.996
Fibrolamellar carcinoma	1 (0.3)	2 (0.5)
Hepatocellular carcinoma	183 (49.9)	181 (49.3)
Overall survival event			0.017
Alive	133 (35.6)	111 (29.7)
Dead	54 (14.4)	76 (20.3)
Disease specific survival event			0.009
No	153 (41.8)	134 (36.6)
Yes	29 (7.9)	50 (13.7)
Progression free interval event			0.005
No	109 (29.1)	82 (21.9)
Yes	78 (20.9)	105 (28.1)

AFP: Alpha-fetoprotein.